Initial Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $3.8M

  • Investors
  • 1

Initial Therapeutics General Information

Description

Developer of small-molecule medicines designed to prevent pathogenic protein synthesis. The company offers an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed, enabling healthcare professionals to address difficult-to-drug targets in areas of serious unmet medical need.

Contact Information

Website
www.initialtx.com
Formerly Known As
Opal Biosciences
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 285 East Grand Avenue
  • Suite 2200
  • San Francisco, CA 94080
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 285 East Grand Avenue
  • Suite 2200
  • San Francisco, CA 94080
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Initial Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-May-2023 $3.8M Completed Startup
To view Initial Therapeutics’s complete valuation and funding history, request access »

Initial Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Initial Therapeutics’s complete cap table history, request access »

Initial Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule medicines designed to prevent pathogenic protein synthesis. The company offers an approach t
Drug Discovery
San Francisco, CA
13 As of 2026

San Diego, CA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Initial Therapeutics Competitors (62)

One of Initial Therapeutics’s 62 competitors is BioTheryx, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioTheryx Venture Capital-Backed San Diego, CA
Arvinas Formerly VC-backed New Haven, CT
Exo Therapeutics Venture Capital-Backed Cambridge, MA
Progenra Formerly VC-backed Malvern, PA
Plexium Venture Capital-Backed San Diego, CA
You’re viewing 5 of 62 competitors. Get the full list »

Initial Therapeutics Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Initial Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024226875-A3 Compounds, compositions and methods for attenuation of mammalian translation of c-myc or n-myc proteins Inactive 28-Apr-2023
US-20240400555-A1 Compounds, compositions and methods for attenuation of mammalian translation of c-myc or n-myc proteins of the myc proto-oncogene family of bhlh transcription factors Pending 28-Apr-2023
WO-2024226875-A2 Compounds, compositions and methods for attenuation of mammalian translation of c-myc or n-myc proteins of the myc proto-oncogene family of bhlh transcription factors Inactive 28-Apr-2023 C07D471/04

Initial Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Initial Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apple Tree Partners (ATP) Venture Capital Minority
To view Initial Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Initial Therapeutics FAQs

  • When was Initial Therapeutics founded?

    Initial Therapeutics was founded in 2020.

  • Where is Initial Therapeutics headquartered?

    Initial Therapeutics is headquartered in San Francisco, CA.

  • What is the size of Initial Therapeutics?

    Initial Therapeutics has 13 total employees.

  • What industry is Initial Therapeutics in?

    Initial Therapeutics’s primary industry is Drug Discovery.

  • Is Initial Therapeutics a private or public company?

    Initial Therapeutics is a Private company.

  • What is the current valuation of Initial Therapeutics?

    The current valuation of Initial Therapeutics is .

  • What is Initial Therapeutics’s current revenue?

    The current revenue for Initial Therapeutics is .

  • How much funding has Initial Therapeutics raised over time?

    Initial Therapeutics has raised $3.8M.

  • Who are Initial Therapeutics’s investors?

    Apple Tree Partners (ATP) has invested in Initial Therapeutics.

  • Who are Initial Therapeutics’s competitors?

    BioTheryx, Arvinas, Exo Therapeutics, Progenra, and Plexium are some of the 62 competitors of Initial Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process